This study is in progress, not accepting new patients
Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.
Summary
- Eligibility
- for females ages 18 years and up (full criteria)
- Location
- at UCLA
- Dates
- study startedcompletion around
- Principal Investigator
- by Joshua Cohen (ucla)
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at University of California Health
- Joshua Cohen (ucla)
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Incyte Corporation
- ID
- NCT04463771
- Phase
- Phase 2 Endometrial Cancer Research Study
- Study Type
- Interventional
- Participants
- About 206 people participating
- Last Updated